Kidney Transplantation Decreases the Level and Procoagulant Activity of Circulating Microparticles

Microparticles (MP) are important players in cardiovascular disorders. Renal transplantation significantly improves the survival of hemodialyzed patients, in part because cardiovascular disease (CVD) progression is lessened. We hypothesized that the beneficial effect of renal transplantation on cardiovascular outcome might involve decreased levels of circulating MP. We evaluated the kinetics of MP subpopulations and their procoagulant activity (MP‐PCA) in 52 patients before and 3, 6, 9 and 12 months after graft with reference to 50 healthy controls and we evaluated the impact of cardiovascular complications. During the follow‐up, the increased levels of MP observed before graft were significantly decreased and reached normal values with different kinetics according to their cellular origin whereas MP‐PCA remained significantly higher than in controls. From multivariate analysis, the levels of MP were negatively correlated with renal function. At 12 months, the decrease in MP and MP‐PCA was more pronounced in patients without history of CVD than those with. In conclusion, we demonstrated that renal graft is associated with decreased levels of MP levels and MP‐PCA, even more pronounced so in patients without history of CVD. Therefore, we suggest that MP lowering could be involved in the vascular dysfunction improvements reported after transplantation.

[1]  Chantal M Boulanger,et al.  Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. , 2005, Journal of the American Society of Nephrology : JASN.

[2]  R. Nieuwland,et al.  Elevated Numbers of Tissue-Factor Exposing Microparticles Correlate With Components of the Metabolic Syndrome in Uncomplicated Type 2 Diabetes Mellitus , 2002, Circulation.

[3]  K. Johny,et al.  Hypercoagulability, a serious problem in patients with ESRD on maintenance hemodialysis, and its correction after kidney transplantation. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  M. Mesri,et al.  Leukocyte Microparticles Stimulate Endothelial Cell Cytokine Release and Tissue Factor Induction in a JNK1 Signaling Pathway* , 1999, The Journal of Biological Chemistry.

[5]  Richard A. Preston,et al.  Effects of Severe Hypertension on Endothelial and Platelet Microparticles , 2003, Hypertension.

[6]  A. Halestrap,et al.  Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. , 1995, The Biochemical journal.

[7]  B. Kasiske,et al.  Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. , 2000, Journal of the American Society of Nephrology : JASN.

[8]  J. Freyssinet,et al.  Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb‐IIIa antagonists , 2004, Journal of thrombosis and haemostasis : JTH.

[9]  H. Shima,et al.  Effect of renal transplantation on the cardiac function of patients with hemodialysis. , 2007, Journal of cardiology.

[10]  P Lesavre,et al.  Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis. , 2006, Kidney international.

[11]  Eld,et al.  COMPARISON OF MORTALITY IN ALL PATIENTS ON DIALYSIS , PATIENTS ON DIALYSIS AWAITING TRANSPLANTATION , AND RECIPIENTS OF A FIRST CADAVERIC TRANSPLANT , 2000 .

[12]  J. Thistlethwaite,et al.  Platelets and capillary injury in acute humoral rejection of renal allografts. , 2003, Human pathology.

[13]  D. Pisetsky,et al.  The Role of Microparticles in Inflammation and Thrombosis , 2007, Scandinavian journal of immunology.

[14]  W. Hörl.  Hemodialysis membranes: interleukins, biocompatibility, and middle molecules. , 2002, Journal of the American Society of Nephrology : JASN.

[15]  A. Halestrap,et al.  Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin. , 1991, The Biochemical journal.

[16]  D. Jay,et al.  Calcineurin dephosphorylates the C-terminal region of filamin in an important regulatory site: a possible mechanism for filamin mobilization and cell signaling. , 2006, Archives of biochemistry and biophysics.

[17]  J. Freyssinet,et al.  Procoagulant Microparticles: Disrupting the Vascular Homeostasis Equation? , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[18]  R. Nieuwland,et al.  Measuring circulating cell‐derived microparticles , 2004, Journal of thrombosis and haemostasis : JTH.

[19]  T. Mori,et al.  The effects of calpeptin (a calpain specific inhibitor) on agonist induced microparticle formation from the platelet plasma membrane. , 1993, Thrombosis research.

[20]  V. Faure,et al.  Elevation of circulating endothelial microparticles in patients with chronic renal failure , 2006, Journal of thrombosis and haemostasis : JTH.

[21]  J. Schold,et al.  Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  A. Tedgui,et al.  Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease. , 2006, Hypertension.

[23]  L. Arnaud,et al.  Impact of Immunosuppressive Treatment on Endothelial Biomarkers After Kidney Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  A. Halestrap,et al.  Protection by Cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. , 1993, Journal of molecular and cellular cardiology.

[25]  M. Kuske,et al.  Assignment1 of the human PHLDA1 gene to chromosome 12q15 by radiation hybrid mapping , 2000, Cytogenetic and Genome Research.

[26]  J. Morrow,et al.  Effect of Renal Transplantation on Biomarkers of Inflammation and Oxidative Stress in End-Stage Renal Disease Patients , 2005, Transplantation.

[27]  Christian Weber,et al.  Platelet Microparticles: A Transcellular Delivery System for RANTES Promoting Monocyte Recruitment on Endothelium , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[28]  Hongying Tang,et al.  The Impact of Recipient History of Cardiovascular Disease on Kidney Transplant Outcome , 2007, ASAIO journal.

[29]  A. Mitwalli,et al.  Successful kidney transplantation does not reverse the coagulopathy in patients with chronic renal failure on either hemo or peritoneal dialysis. , 2007, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

[30]  J. Hooff,et al.  Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients , 2001, Transplant international : official journal of the European Society for Organ Transplantation.

[31]  A. Simon,et al.  Circulating Leukocyte-Derived Microparticles Predict Subclinical Atherosclerosis Burden in Asymptomatic Subjects , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[32]  P. Houillier,et al.  Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. , 2005, Journal of the American Society of Nephrology : JASN.

[33]  B. Goichot,et al.  Circulating procoagulant microparticles in obesity. , 2006, Diabetes & metabolism.

[34]  G. Danovitch,et al.  Cardiovascular disease posttransplant. , 2007, Seminars in nephrology.

[35]  R. Wolfe,et al.  Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. , 2001, Journal of the American Society of Nephrology : JASN.

[36]  J. Freyssinet,et al.  Procoagulant Microparticles: ‘Criminal Partners’ in Atherothrombosis and Deleterious Cellular Exchanges , 2006, Pathophysiology of Haemostasis and Thrombosis.

[37]  R. Andriantsitohaina,et al.  Origin and biological significance of shed-membrane microparticles. , 2006, Endocrine, metabolic & immune disorders drug targets.